AMS

American Shared Hospital Services is a provider of turn-key technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services. Its segments include Leasing and Retail. The Leasing segment comprises the Company’s medical equipment leasing. The Retail segment comprises facilities in Peru and Ecuador. Its Proton Beam Radiation Therapy Operations is an alternative to traditional external beam, photon-based radiation delivered by linear accelerators. Its Gamma Knife stereotactic radiosurgery, a non-invasive procedure, is an alternative to conventional brain surgery and/or radiation therapy. The Gamma Knife treats selected malignant and benign brain tumors, arteriovenous malformations, and functional disorders including trigeminal neuralgia (facial pain). It can be an adjunct to conventional brain surgery, radiation therapy, or chemotherapy. The Company provides radiation therapy services both domestically and internationally.

Wall Street analysts forecast AMS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMS is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

American Shared Hospital Services revenue for the last quarter amounts to 7.17M USD, increased 2.46 % YoY.

American Shared Hospital Services. EPS for the last quarter amounts to -0.00 USD, decreased -100.00 % YoY.

American Shared Hospital Services (AMS) has 81 emplpoyees as of December 15 2025.

Today AMS has the market capitalization of 14.07M USD.